Abstract
Variations in HTA outcomes can primarily be explained with reference to institutional context and administrative rules. Here we focus on the German Federal Joint Committee (Gemeinsamer Bundesausschuss, GBA), the French Haute Autorité de Santé (HAS) and the British National Institute for Health and Care Excellence (NICE) to identify matched drug pairs as a basis to compare HTA outcomes and to analyze cancer-related HTA results in detail.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
